SEC Form 4 · accession 0001193125-26-267493
Kailera Therapeutics, Inc. · KLRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald C Renaud Jr.
Officer — CEO & President · Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002096997
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 9, 2026 | M | 38,094 | $5.25 | A | 38,094 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.25 | Jun 9, 2026 | M | 38,094 | D | — | Sep 19, 2034 | Common Stock | 38,094 | 817,826 | D |
Explanation of responses
- F1The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.